跳至主要内容
临床试验/NCT00590629
NCT00590629已完成4 期

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

Cedars-Sinai Medical Center2 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2002年6月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
43
试验地点
2

研究概览

简要总结

Several risk factors including high cholesterol contribute to heart disease. We know that lowering triglycerides and raising HDL (protective cholesterol) in men reduces the risk for heart disease. We expect that women will share this same benefit because the combination of high triglycerides and low HDL appears to be a more important risk for heart disease in women. Niacin reduces triglycerides and raises HDL. We also expect to see improvement in markers of inflammation and clot formation and blood vessel health, which we hypothesize should all confer a reduced risk of heart disease in women.

Women already taking lipid lowering statin will receive niacin therapy. We will measure blood lipid levels, markers of inflammation and clotting as well as a non-invasive measure of blood vessel reactivity. After 3 months of therapy we will repeat these measures.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Stable women on statin therapy with LDL-C between 90-135mg/dl and triglycerides > 150mg/dl

排除标准

  • History of MI, PTCA or surgery within previous 3 months
  • Currently on Niaspan and unwilling to withdraw Niaspan therapy or known intolerance to niacin
  • Active or known gall bladder disease
  • Pregnant or nursing women
  • Significant comorbidity that precludes participation
  • Significant liver disease, active alcoholism, or LFT >1.5x's ULN at screening
  • Diabetes or glucose > 126 mg/dl at screening
  • PI perceived inability to comply with protocol

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验